CN102805730A - Ceramide liposome and preparation method and application thereof - Google Patents
Ceramide liposome and preparation method and application thereof Download PDFInfo
- Publication number
- CN102805730A CN102805730A CN2012100664643A CN201210066464A CN102805730A CN 102805730 A CN102805730 A CN 102805730A CN 2012100664643 A CN2012100664643 A CN 2012100664643A CN 201210066464 A CN201210066464 A CN 201210066464A CN 102805730 A CN102805730 A CN 102805730A
- Authority
- CN
- China
- Prior art keywords
- ceramide
- liposome
- ceramide liposome
- phospholipid
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940106189 ceramide Drugs 0.000 title claims abstract description 155
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title claims abstract description 154
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title claims abstract description 154
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title claims abstract description 154
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 title claims abstract description 150
- 239000002502 liposome Substances 0.000 title claims abstract description 137
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 56
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 28
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 22
- 239000003960 organic solvent Substances 0.000 claims abstract description 17
- 239000000126 substance Substances 0.000 claims abstract description 12
- 239000004094 surface-active agent Substances 0.000 claims abstract description 12
- 239000000654 additive Substances 0.000 claims abstract description 10
- 239000000232 Lipid Bilayer Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- -1 palmityl phosphatidic acid, dioleoyl phospholipid Chemical class 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 15
- 230000004087 circulation Effects 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 10
- 229960000502 poloxamer Drugs 0.000 claims description 10
- 229920001983 poloxamer Polymers 0.000 claims description 10
- 239000010409 thin film Substances 0.000 claims description 10
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- 239000008363 phosphate buffer Substances 0.000 claims description 9
- 229940083466 soybean lecithin Drugs 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000000787 lecithin Substances 0.000 claims description 8
- 235000010445 lecithin Nutrition 0.000 claims description 8
- 229940067606 lecithin Drugs 0.000 claims description 8
- 239000008176 lyophilized powder Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 102000002322 Egg Proteins Human genes 0.000 claims description 6
- 108010000912 Egg Proteins Proteins 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 239000003223 protective agent Substances 0.000 claims description 6
- 239000006247 magnetic powder Substances 0.000 claims description 5
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 241000287828 Gallus gallus Species 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 4
- 239000010408 film Substances 0.000 claims description 4
- 210000004681 ovum Anatomy 0.000 claims description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 claims description 2
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 claims description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241000272525 Anas platyrhynchos Species 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 239000004380 Cholic acid Substances 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 239000004201 L-cysteine Substances 0.000 claims description 2
- 235000013878 L-cysteine Nutrition 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- 229930182844 L-isoleucine Natural products 0.000 claims description 2
- 244000147568 Laurus nobilis Species 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 150000003851 azoles Chemical class 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 125000001549 ceramide group Chemical group 0.000 claims description 2
- 229940099352 cholate Drugs 0.000 claims description 2
- 235000019416 cholic acid Nutrition 0.000 claims description 2
- 229960002471 cholic acid Drugs 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims description 2
- 235000013345 egg yolk Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 229960002598 fumaric acid Drugs 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940099690 malic acid Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 2
- 229940067626 phosphatidylinositols Drugs 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- 229940001482 sodium sulfite Drugs 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 230000008542 thermal sensitivity Effects 0.000 claims description 2
- 238000000015 thermotherapy Methods 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 238000009827 uniform distribution Methods 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000002245 particle Substances 0.000 abstract description 4
- 230000000996 additive effect Effects 0.000 abstract 2
- 239000002612 dispersion medium Substances 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 42
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 28
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 28
- 238000011580 nude mouse model Methods 0.000 description 25
- 229960005277 gemcitabine Drugs 0.000 description 23
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical class O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 23
- 241000699660 Mus musculus Species 0.000 description 22
- 229940079593 drug Drugs 0.000 description 21
- 208000008443 pancreatic carcinoma Diseases 0.000 description 20
- 230000004083 survival effect Effects 0.000 description 16
- 229930012538 Paclitaxel Natural products 0.000 description 13
- 230000006872 improvement Effects 0.000 description 13
- 229960001592 paclitaxel Drugs 0.000 description 13
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 201000002528 pancreatic cancer Diseases 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- NPRJSFWNFTXXQC-QFWQFVLDSA-N N-(hexanoyl)sphing-4-enine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCC NPRJSFWNFTXXQC-QFWQFVLDSA-N 0.000 description 8
- 239000012930 cell culture fluid Substances 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 230000006837 decompression Effects 0.000 description 6
- 229960000935 dehydrated alcohol Drugs 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 229940087168 alpha tocopherol Drugs 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 229960000984 tocofersolan Drugs 0.000 description 4
- 239000002076 α-tocopherol Substances 0.000 description 4
- 235000004835 α-tocopherol Nutrition 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000005243 fluidization Methods 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940084106 spermaceti Drugs 0.000 description 2
- 239000012177 spermaceti Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940039946 soybean lecithin 1200 mg Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940104757 vitamin E 50 mg Drugs 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to ceramide liposome and a preparation method and application thereof. The ceramide liposome comprises a therapeutically effective amount of active component and a lipid bilayer film, and is characterized in that the ceramide liposome comprises 0.5 to 20 weight parts of ceramide used as the active component and 10 to 350 weight parts of the lipid bilayer film, wherein the lipid bilayer film comprises the following components in part by weight: 5 to 100 parts of phospholipid substance, 0.5 to 10 parts of cholesterol, 0 to 100 parts of surfactant, 0 to 20 parts of additive and 0.5 to 10 parts of organic solvent. The preparation method comprises the following steps of: fully dissolving the ceramide, the phospholipid substance, the cholesterol and the additive in the organic solvent, dissolving the surfactant in a dispersion medium to prepare the ceramide liposome, and reducing the average particle size of the prepared ceramide liposome to less than 500nm to ensure that the particle sizes are uniformly distributed. The invention also discloses new application of the ceramide liposome to cancer therapy.
Description
Technical field
The invention belongs to technical field of medicine, specifically relate to targeting drug administration preparation short chain ceramide liposome and preparation method thereof, with and new purposes in oncotherapy.
Background technology
Malignant tumor has become the disease that the disease death rate ranks the first, and chemotherapy is one of topmost treatment means.Most late tumor patients all need chemotherapy, and chemotherapy is that whole body cancerous cell diffusion patient is than effective method.But the total effective percentage of chemotherapy is still less than 30% at present clinical, and nearly all chemotherapeutic all can produce the multidrug resistance phenomenon in treatment, thereby further reduced the chemotherapy effective percentage.Therefore, the therapeutic effect that how to improve chemotherapeutics is the key issue of oncotherapy.
Short chain ceramide (C2, C4, C6, C8, first-selected C6) is a kind of lipid molecular that is produced by the hydrolysis of cell membrane sphingomyelin, and it is present in the cell membrane with high concentration, belongs to lipid molecule family, has constituted sphingol and fatty acid.It can bring into play second message,second messenger's in the cell effect discovered in recent years, has mediated the various kinds of cell biological effect, comprises cell differentiation, growth inhibited, apoptosis, immunoreation etc.Ceramide has also been participated in the activation expression regulation of antioncogenes such as JNK, p53, bcl-2, p21.Research recently shows that lonizing radiation, chemotherapeutics (paclitaxel, doxorubicin, daunorubicin etc.), oxidative stress etc. can activate ceramide signaling system in the tumor cell, and synthetic ceramide promotes apoptosis in the inducing cell body.In addition, the stimulation that ceramide gathers in any enhancing cell all can produce apoptosis-promoting effect, and the tumor cell that can not produce enough ceramides can not effectively carry out apoptosis usually.To most tumor cell, endogenic ceramide is inducing apoptosis of tumour cell effectively.Therefore, exogenous interpolation ceramide is as chemotherapeutic sensitizer, thereby effectively increases chemotherapy drug susceptibility, and reducing chemotherapy resistance is an efficacious therapy approach.
However, whole body utilization ceramide still receives its physics, chemistry affect.Because ceramide is hydrophobic fat-soluble, carry in the body and form big aggregation, be difficult to arrive in the tumor cell.Even adding solubilizing agent polyoxy ethyl Oleum Ricini is mixed with injection and also is prone to cause more complication, and is low like anaphylaxis and bioavailability.Liposome is little to the body toxic and side effects, and its lipid bilayer and biomembrane have bigger similarity and tissue intersolubility, are easy to by tissue absorption.Wrapping kmedicine by liposome is a physical process, does not change drug molecular structure, after medicine is wrapped, can reduce drug toxicity, reduces the drug use amount, has slow release and controlled-release function.Therefore, the ceramide liposome of exploitation target tumor position, long circulation slow-release function seems particularly important to satisfy the clinical administration demand.
At present, still do not have the ceramide liposome (comprising injection or peroral dosage form) that can be used for oncotherapy both at home and abroad, therefore, our invention has fabulous novelty.
Summary of the invention
The objective of the invention is to overcome the deficiency that exists in the prior art; But develop the ceramide liposome (comprising injection or peroral dosage form) of a kind of stable in properties and suitability for industrialized production; The method for preparing of ceramide liposome is provided simultaneously, and discloses the new purposes of this ceramide liposome in oncotherapy.
First purpose of the present invention realizes through following technical scheme:
Ceramide liposome comprises a treatment effective amount of actives and a type lipid bilayer thin film, and it is characterized in that: the weight portion of said active component is 0.5-20 part, and active component is a ceramide; The weight portion of said type of lipid bilayer thin film is 10-350 part, comprises following components by part by weight: phospholipid substance 5-100 part, cholesterol 0.5-10 part, surfactant 0-100 part, additives 0-20 part, organic solvent 0.5-10 part.
As further improvement of the present invention, described phospholipid substance is selected from one or more in two Laurel phosphatidyl cholines, DSPC, distearyl phosphatidyl glycerol, Phosphatidylserine, phosphatidylinositols, two palmityl phosphatidic acid, dioleoyl phospholipid phatidylcholine, dimyristoyl phosphatidyl choline, phosphatidyl glycerol, phosphatidic acid, phosphatidylcholine, dipalmitoyl phosphatidyl choline, two palmityl phosphatidyls, DOPE, soybean lecithin, Ovum Gallus domesticus Flavus lecithin, cephalin, synthetic phospholipid, the hydrogenated soy phosphatidyl choline.
As further improvement of the present invention, it is the natural cholesterol of raw material production that said cholesterol is selected for use with egg yolk, animal brains, lanoline.
As further improvement of the present invention, said surfactant is selected from one or more the compositions in dexycholate, cholate, deoxycholic acid, cholic acid, tween 80, taurocholate, the poloxamer.
As further improvement of the present invention, said organic solvent is selected from one or more the mixture in ethanol, acetone, methanol, chloroform, ether, the isopropyl alcohol.
As further improvement of the present invention, said additives are selected from one or more among L-isoleucine, malic acid, sodium metabisulfite, sodium sulfite, vitamin C, vitamin E, propyl gallate, fumaric acid, L-cysteine or PH buffer agent phosphate, the EDTA.
As further improvement of the present invention, said ceramide liposome adds long circulation adjuvant, carries out finishing and processes long circulating liposomes, and the mol ratio of long circulation adjuvant of said long circulation adjuvant and phospholipid substance is 1:10-1:200; Said long circulation adjuvant is selected from Polyethylene Glycol-phospholipid derivative, Polyethylene Glycol, polyvinylpyrrolidone, methyl and gathers azoles quinoline, Polyethylene Glycol-dipalmitoyl phosphatidyl choline, Polyethylene Glycol-distearyl acyl group PHOSPHATIDYL ETHANOLAMINE, chitosan or polyvinyl alcohol.
As further improvement of the present invention, said ceramide liposome adds the magnetic decorative material, carries out finishing and processes magnetic liposome; Said magnetic decorative material is a super-fine magnetic powder.
As further improvement of the present invention, said ceramide liposome adds the temperature-sensitive auxiliary material, carries out finishing and processes thermal sensitive liposome; Said temperature-sensitive auxiliary material are the phospholipid that itself has thermal sensitivity, comprise dipalmitoyl phosphatidyl choline (DPPC), DSPC (DSPC); Or the macromolecule thermally sensitive polymeric, comprise polyacrylic acid, gather phosphatidic acid; Or a kind of phase transition temperature that can make liposome is suitable for the oiliness medicine of tumor thermotherapy temperature, comprises elemene or wild duck seed oil.
Traditional liposome particle diameter is bigger, and low, the poor stability of envelop rate is removed it by the phagocyte of reticuloendothelial system especially easily from blood circulation, thereby reduces the dose that arrives tumor tissues.The present invention carries out finishing to liposome; The long circulating liposomes of processing, magnetic liposome, thermal sensitive liposome etc. can further prolong the blood circulation time of ceramide liposome; Improve the targeting property and the bioavailability of ceramide liposome, reduce toxic and side effects.
As further improvement of the present invention, the mean diameter of said ceramide liposome decentralized photo is less than 500nm.
As further improvement of the present invention, said ceramide liposome exists with the form of injection or solid powder.The form of solid powder can prolong the resting period of ceramide liposome greatly, is convenient to transportation.
Ceramide liposome of the present invention can be with injection or oral way administration, and wherein injection system can be intravenous drip, intravenous injection.Subcutaneous injection, intramuscular injection, lumbar injection etc., preferred intravenous injection.
As further improvement of the present invention, said ceramide liposome envelop rate is greater than 80%.
Second purpose of the present invention realizes through following technical scheme:
The method for preparing of ceramide liposome; It is characterized in that; Comprise the steps: fully to be dissolved in ceramide, phospholipid substance, cholesterol and additives in the organic solvent; In disperse medium, adopt film dispersion method or organic solvent injection method to make ceramide liposome surfactant dissolves, adopt ultrasonic, high pressure homogenize then or the method extruded is reduced to below the 500nm mean diameter of the ceramide liposome that makes and uniform distribution.
The detail operations of said film dispersion method is: fully be dissolved in ceramide, phospholipid substance, cholesterol and additives in the organic solvent; This solution is placed in the rotary evaporator; At 40 ℃ of removal organic solvents that reduce pressure down; Form thin film, add the pH value that contains surfactant then and be 3.0 ~ 10.0 disperse medium, make ceramide liposome.
The detail operations of said organic solvent injection method is: fully be dissolved in ceramide, phospholipid substance, cholesterol and additives in the organic solvent; It is 3.0 ~ 10.0 disperse medium that this solution is slowly injected 50-60 ℃ the pH value that contains surfactant; Being stirred to organic solvent with the electronics constant speed stirrer eliminates; The described disperse medium of reuse is diluted to and requires concentration, makes ceramide liposome.
As the further improvement of said method for preparing, said disperse medium is Tris buffer, water, phosphate buffer, carbonate buffer solution, 5% D/W or 0.9%NaCl solution; The weight concentration of the surfactant in the said disperse medium is 1%-30%.
As the further improvement of said method for preparing, in the ceramide liposome that makes, add the lyophilized powder protective agent, process lyophilized powder through spray drying or freeze drying process; Said lyophilized powder protective agent is selected from one or more in mannitol, sucrose, trehalose, sodium chloride, glucose, dextran, glycine, lactose, sorbitol, xylitol, fructose, glycerol, arabic gum and the lysine; The lyophilized powder protective agent: the parts by weight proportioning of ceramide liposome is (10-20): (0.5-6.0).
The 3rd purpose of the present invention is:
The purposes of described ceramide liposome in the preparation antitumor drug is provided.
The present invention compared with prior art, advantage is:
The ceramide liposome of the present invention's preparation can have certain targeting property to tumor; Long circulating liposomes can significantly improve liposome circulation time in vivo; Make medicine more long-term effectively targeting in tumor locus; And chemotherapeutics (as: taxanes and gemcitabine class medicine etc.) unite utilization can be more effective inducing apoptosis of tumour cell, reduce chemotherapeutics concentration and avoid chemotherapy resistance, prolonged the biological time-to-live.
Description of drawings
Fig. 1 is to the situation that the influences curve chart of mean tumour volume of the transplanted tumor in nude mice of inoculation pancreatic cancer cell after different drug or the drug regimen administration.
Fig. 2 is to the inhibition situation pictorial diagram of final size of the transplanted tumor in nude mice of inoculation pancreatic cancer cell after different drug or the drug regimen administration.
Fig. 3 is to the situation that the influences curve chart of mean survival time of the nude mice of inoculation pancreatic cancer cell after different drug or the drug regimen administration.
Fig. 4 is to the situation that the influences curve chart of mean tumour volume of the transplanted tumor in nude mice of inoculation pancreatic cancer cell after different drug or the drug regimen administration.
Fig. 5 is to the situation that the influences curve chart of survival rate of the nude mice of inoculation pancreatic cancer cell after different drug or the drug regimen administration.
Fig. 6 is the situation that the influences bar diagram to the cell survival rate of people MIA pancreas cancer cell strain of the different drug that records of mtt assay or drug regimen.
Fig. 7 is the situation that the influences bar diagram to the cell survival rate of people CaOV3 ovarian cancer cell strain of the different drug that records of mtt assay or drug regimen.
Fig. 8 is the situation that the influences bar diagram to the cell survival rate of L3.6 pancreas cancer cell strain of the different drug that records of mtt assay or drug regimen.
The specific embodiment
Below in conjunction with concrete accompanying drawing and embodiment the present invention is described further.
Ceramide 20mg
Ovum Gallus domesticus Flavus lecithin 20mg
Cholesterol 200mg
Ether 10ml
Taurocholate 30mg
Method for making: the 30mg taurocholate is dissolved in the phosphate buffer (pH 7.4), and the weight concentration of taurocholate in phosphate buffer is 15%; 20mg ceramide, 20mg Ovum Gallus domesticus Flavus lecithin and 200mg cholesterol are dissolved in the ether; Then this solution is slowly injected 50-60 ℃ phosphate buffer; Being stirred to ether with the electronics constant speed stirrer with the 600r/min rotating speed eliminates; The above-mentioned phosphate buffer of reuse is diluted to 100ml, promptly gets ceramide liposome, puts 4 ℃ of preservations.
Soybean lecithin 120mg
Cholesterol 250mg
Methanol 10ml
Ethanol 10ml
NaTDC 40mg
Method for making: the 40mg NaTDC is dissolved in the Tris-HCl that an amount of molar concentration is 20mmol/L (PH7.5 the contains 0.15mol/LNaCl) buffer, and the weight concentration of NaTDC in the Tris-HCl buffer is 10%; The 30mg ceramide is dissolved in the 10ml methanol, and 120mg lecithin, 250mg cholesterol are dissolved in the 10ml ethanol, place these two kinds of solution in the rotary evaporator jointly; Remove solvent 40 ℃ of decompressions, form thin film, add above-mentioned then; Add the above-mentioned Tris-HCl buffer that is dissolved with NaTDC then; Supersound process 30min promptly gets ceramide liposome, the spray-dried lyophilized formulations that makes ceramide liposome.Only need abundant aquation to shake in short-term before lyophilized formulations uses, just can form ceramide liposome again.
Ceramide 100mg
Soybean lecithin 1200mg
Hydrogenation saturated phospholipid 300mg
Cholesterol 100mg
Ganglioside 50mg
Dehydrated alcohol 50ml
Vitamin E 50mg
Method for making: with 100mg ceramide, 1200mg soybean lecithin, 300mg hydrogenation saturated phospholipid, 100mg cholesterol, 50mg ganglioside and 6.5mg vitamin E ultrasonic dissolution in the 50ml dehydrated alcohol; Solvent is removed in the 40 ℃ of decompressions in rotary evaporator of this solution, form thin film, add 20mmol/L Tris-HCl (PH7.5 then; Contain 0.15mol/LNaCl) buffer; Supersound process 30min, high pressure homogenizer circulation homogenizing 5-6 time is crossed 0.22 μ m microporous filter membrane then; The packing embedding gets ceramide liposome, through the dry lyophilized formulations that gets ceramide liposome.Only need abundant aquation to shake in short-term before lyophilized formulations uses, just can form liposome again.
C6 ceramide 250mg
Soybean lecithin 1500mg
Hydrogenation saturated phospholipid 500mg
Cholesterol 150mg
Vitamin E 7.2mg
Oleic acid 50mg
Poloxamer 50mg
Dehydrated alcohol 10ml
Method for making: the 50mg poloxamer is dissolved in the Tris-HCl that an amount of molar concentration is 20mmol/L (PH7.5 the contains 0.15mol/LNaCl) buffer, and the weight concentration of poloxamer in the Tris-HCl buffer is 15%; With 250mg C6 ceramide, 1500mg soybean lecithin, 500mg hydrogenation saturated phospholipid, 150mg cholesterol, 7.2mg vitamin E and 50mg oleic acid and ultrasonic dissolution in the 10ml dehydrated alcohol; Solvent is removed in the 40 ℃ of decompressions in rotary evaporator of this solution, form thin film, add then; Add the above-mentioned Tris-HCl buffer that is dissolved with poloxamer then; Supersound process 30min, high pressure homogenizer circulation homogenizing 5-6 time is crossed the 0.22um microporous filter membrane then; The packing embedding gets ceramide liposome, through the dry lyophilized formulations that gets ceramide liposome.Only need abundant aquation to shake in short-term before lyophilized formulations uses, just can form ceramide liposome again.
Embodiment 5: the ceramide liposome of dual-target tumor
C6 ceramide 250mg
Soybean lecithin 1500mg
Hydrogenation saturated phospholipid 500mg
Cholesterol 150mg
Vitamin E 7.2mg
Oleic acid 50mg
Poloxamer 50mg
Dehydrated alcohol 10ml
The polypeptide of dual-target tumor: adopt the 9-FMOC solid-phase synthesis synthetic, adopt the HPLC purification, adopt mass spectrum to identify.
Method for making: the 50mg poloxamer is dissolved in the Tris-HCl that an amount of molar concentration is 20mmol/L (PH7.5 the contains 0.15mol/LNaCl) buffer, and the weight concentration of poloxamer in the Tris-HCl buffer is 15%; With 250mg C6 ceramide, 1500mg soybean lecithin, 500mg hydrogenation saturated phospholipid, 150mg cholesterol, 7.2mg vitamin E, 50mg oleic acid ultrasonic dissolution in the 10ml dehydrated alcohol; Solvent is removed in the 40 ℃ of decompressions in rotary evaporator of this solution; Form thin film, add the above-mentioned Tris-HCl buffer that is dissolved with poloxamer then, supersound process 30min; High pressure homogenizer circulation homogenizing 5-6 time; Cross the 0.22um microporous filter membrane then, make ceramide liposome, in this ceramide liposome, add the polypeptide of dual-target tumor; Ceramide liposome: the mol ratio of the polypeptide of dual-target tumor is 1:50, through the dry lyophilized formulations that gets the ceramide liposome of dual-target tumor.Only need abundant aquation to shake in short-term before this lyophilized formulations uses, just can form ceramide liposome again.
Embodiment 6: the preparation of ceramide long circulating liposomes
Ceramide 20mg
Hydrogenated soy phosphatidyl choline 200mg
Cholesterol 100mg
PEG-DSPE 50mg
Chloroform 30ml
Alpha-tocopherol 20mg
Method for making: 20mg ceramide, 50mg PEG-DSPE, 200mg hydrogenated soy phosphatidyl choline, 100mg cholesterol and 20mg alpha-tocopherol are dissolved in the 30ml chloroform, put in the pyriform bottle rotary evaporation under nitrogen current; Solvent is removed in decompression, vacuum drying 2-3 days then, gets the constant weight thin film; Tris-HCl buffer (the PH7.0 that adds an amount of 20mmol/L again; Contain 0.15mol/L NaCl), the pyriform bottle is shaken in rotation, obtains the liposome suspension.Behind nitrogen wash, sealed under the room temperature balance 1 day, probe sonication 15min, then under 500Kpa pressure through little fluidization phase mixing chamber, handle through little fluidization of 60-80 stroke, make the liposome particle diameter less than 100nm.With 5.4% glucose solution dialysis desalination, get neural amide long circulating liposomes then, process lyophilized formulations through lyophilized preparation again.Only need abundant aquation to shake in short-term before this lyophilized formulations uses, just can form ceramide liposome again.
Embodiment 7: the preparation of ceramide thermal sensitive liposome
Ceramide 0.4g
Injection fabaceous lecithin 20g
Cholesterol 2.4g
Dipalmitoyl phosphatidyl choline (DPPC) 5.0g
18-amine. 0.1g
Vitamin E 0.2g
Ether 200ml
Method for making: the vitamin E of the dipalmitoyl phosphatidyl choline of the cholesterol of the injection fabaceous lecithin of the ceramide of 0.4g, 20g, 2.4g, 5.0g, 0.2g is dissolved in the diethyl ether solution and pours the pyriform bottle into; Add a small amount of PH buffer agent phosphate solution contain 18-amine. again, ultrasonicly make into even breast, decompression eliminates organic solvent on the Rotary Evaporators; Make into gel; Whirlpool concussion distilling under reduced pressure at interval gets white even liposome solutions, and the reuse buffer dissolves to 200ml surely.Remove thermal source through the film that pressurizeed (0.22um) granulate, divide to be filled to lyophilization in the cillin bottle, repeat 3 times, get neural amide thermal sensitive liposome.
Embodiment 8: the preparation of ceramide magnetic liposome
Ceramide 20mg
Soybean lecithin 100mg
Cholesterol 100mg
Two spermaceti phosphatidic acid 20mg
Alpha-tocopherol 20mg
Ether 20ml
Method for making: super-fine magnetic powder is dissolved in the phosphate buffer (pH 7.4), and the weight concentration of super-fine magnetic powder in phosphate buffer is 0.5%; 100mg lecithin, 100mg cholesterol, the two spermaceti phosphatidic acid of 20mg, 20mg alpha-tocopherol and 20mg ceramide are dissolved in the 20ml ether; Form one deck lipid membrane on evaporation under reduced pressure removed organic solvent to the bottle inwall, add the above-mentioned phosphate buffer that contains super-fine magnetic powder, ultrasonic to mixture formation single_phase system on water-soluble type Ultrasound Instrument; Reduction vaporization is to gel formation again; Continue reduction vaporization to forming the muddy liquid of aqueous, inflated with nitrogen, ice-bath ultrasonic promptly gets neural amide magnetic liposome; Add 8% lactose and do caffolding agent, process lyophilized formulations through lyophilized preparation again.
Experimental example 9: the anti-cancer of pancreas effect of ceramide liposome and chemotherapeutics paclitaxel drug combination.
Laboratory animal: the BALB/c male nude mouse at 2 monthly ages (available from Shanghai Si Kelai laboratory animal company), totally 40.
Test method:
The ceramide liposome that we select embodiment 4 and embodiment 5 to make is defined as ceramide liposome 1 and ceramide liposome 2 respectively.
Be based upon body nude mice cancer of pancreas model by following method: nude mice is near right thigh subcutaneous injection 1 * 10
6The L3.6 pancreas cancer cell strain, after 2 weeks, treat visible 50mm
3Behind the entity tumor,, nude mice is divided into 4 groups by 10 every group, is respectively 1 group of matched group, paclitaxel group, paclitaxel+ceramide liposome, 2 groups of the paclitaxel+ceramide liposomes of not administration according to the difference of intravenous administration amount.
Be administered once by preceding 6 day every day, per mode that was administered once in 2 days was carried out administration in back 6 days, carried out altogether 12 days.2 record tumor sizes, nude mice survival rate and body weight write down for 6 weeks altogether weekly, and the record result sees Fig. 1 ~ Fig. 3.
Among Fig. 2: a. contrast, b. paclitaxel, c. paclitaxel+ceramide liposome 1, d. paclitaxel+ceramide liposome 2.
By finding out among Fig. 1 ~ Fig. 3: the exogenous paclitaxel that singly adds, the matched group of tumor size, nude mice survival rate and not administration is obviously difference not; But associating or combination give paclitaxel and ceramide liposome, but can significantly suppress tumor growth, reduce gross tumor volume, prolong the nude mice time-to-live, increase the nude mice survival rate.This conjoint therapy rings not quite the nude mouse ghost image in addition, points out it limited to normal structure and cytotoxic effect.
Above experimentation shows, short chain ceramide paclitaxel and the transplanted tumor in nude mice of inoculation pancreatic cancer cell all had certain antitumor activity, but the tumor killing effect that singly adds ectogenic short chain ceramide or paclitaxel is limited.Short chain ceramide and pharmaceutical preparation thereof just have significant antitumor activity to the transplanted tumor in nude mice of inoculating pancreatic cancer cell after need uniting paclitaxel.
Embodiment 10: the anti-cancer of pancreas effect of ceramide liposome and chemotherapeutics gemcitabine drug combination.
Laboratory animal: the BALB/c male nude mouse at 2 monthly ages (available from Shanghai Si Kelai laboratory animal company), totally 30.
Test method:
Gemcitabine is the goldstandard medicine of pancreatic cancer chemotherapy.The ceramide liposome that we select embodiment 6 to make.
Be based upon body nude mice cancer of pancreas model by following method: nude mice is near right thigh subcutaneous injection 1 * 10
6The L3.6 pancreas cancer cell strain, after 2 weeks, treat visible 50mm
3Behind the entity tumor,, nude mice is divided into 3 groups by 10 every group, is respectively matched group, gemcitabine group, the gemcitabine+ceramide liposome group of not administration according to the difference of intravenous administration amount.
Be administered once by preceding 6 day every day, per mode that was administered once in 2 days was carried out administration in back 6 days, carried out altogether 12 days.Write down gross tumor volume and nude mice survival rate 2 times weekly, write down for 6 weeks altogether, the record result sees Fig. 4, Fig. 5.
Among Fig. 4: A. matched group (tumor DT Doubling Time 5.6 days); B. gemcitabine (tumor DT Doubling Time 5.4 days); C. gemcitabine+ceramide liposome (the tumor DT Doubling Time is 9.1 days); Heteroplastic transplantation cancer of pancreas nude mice growth curve-gemcitabine 5 mg/kg that swell and ache.
Fig. 5: heteroplastic transplantation cancer of pancreas nude mice survival rate
A. contrast; B. gemcitabine; C. add gemcitabine+ceramide liposome.
By finding out among Fig. 4, Fig. 5: the exogenous gemcitabine that singly adds, the matched group of gross tumor volume, nude mice survival rate and not administration be obviously difference not; But associating or combination give gemcitabine and ceramide liposome, but can significantly suppress tumor growth, reduce gross tumor volume, increase the nude mice survival rate.
Embodiment 11: ceramide liposome is to the propagation inhibition test of the human pancreas cancer cell strain of In vitro culture.
The test cell: people MIA pancreas cancer cell strain derives from US mode culture collection warehousing (ATCC).
Test drug and reagent: ceramide (Avanti, USA), 3-(4,5-dimethylthiazole-2)-2,5-diphenyl tetrazole bromine salt (MTT) (sigma, USA); Trypsin sigma, USA); Dimethyl sulfoxine (DMSO) (sigma, USA); The DMEM cell culture medium (GIBCO, Invitragen, USA); The RPMI1640 cell culture fluid (GIBCO, Invitragen, USA); Hyclone (GIBCO, Invitragen, USA); Superfine hyclone Fetal Bovine Serum (Hyclone).
Instrument: ultra cold storage freezer (Nature, USA), inverted microscope (NIKON, Japan), ELIASA (Bio-Tek Instruments, USA); Cell culture incubator (SANYO, Japan), superclean bench (FLC-Harbin Dong Lian instrument plant), the PH meter (Thermo orion, USA).
Experimental technique:
Adopt mtt assay by routine: with people MIA pancreas cancer cell strain by conventional method cultivations of going down to posterity, the cell of collection exponential phase, the adjusting concentration of cell suspension is 5*10
4About individual/ml.
Cell suspension is added in 96 well culture plates, and each hole adds 180 μ l; Place 37 ℃ of constant incubators to cultivate 24h.
Gemcitabine and ceramide liposome (ceramide liposome that embodiment 6 makes) are made into the solution of gradient concentration (0.75 μ g/ml, 1.5 μ g/ml, 3 μ g/ml) respectively with the DMEM cell culture fluid.Experimental group adds Jixitabin solution (A), the ceramide liposome+gemcitabine mixed solution (B) of each concentration; They add by above-mentioned concentration simultaneously; Every hole adds 20 μ l, establishes 4 parallel holes for every group, and establishes blank well (only adding the DMEM cell culture fluid) with zeroing.
Cultivate 48h at 37 ℃ of incubators, with the exhaustion of the liquid in 96 well culture plates, it is the MTT solution of 1mg/ml that every then hole adds 30 μ l concentration, puts 37 ℃, 5%CO with liquid-transfering gun
2Incubator continue to cultivate 4h.
Abandon supernatant, every hole adds dimethyl sulfoxine (DMSO) 150 μ l, puts shaking table and shakes up 30min, under 492nm, detects every hole absorbance (A) value with ELIASA, uses SPSS software statistics experimental result then, and is specifically as shown in Figure 6.
Can find out that by Fig. 6 associating or combination give the survival rate that gemcitabine and ceramide liposome significantly reduce people MIA pancreas cancer cell strain, cause people MIA pancreas cancer cell strain significantly dead, obviously be superior to the anti-cancer of pancreas effect of list with gemcitabine.
Embodiment 12: ceramide liposome is to the propagation inhibition test of the Proliferation of Human Ovarian Cell of In vitro culture.
The test cell: the strain of people CaOV3 ovarian cancer cell derives from US mode culture collection warehousing (ATCC).
Test drug and reagent: ceramide (Avanti, USA), 3-(4,5-dimethylthiazole-2)-2,5-diphenyl tetrazole bromine salt (MTT) (sigma, USA); Trypsin sigma, USA); Dimethyl sulfoxine (DMSO) (sigma, USA); The DMEM cell culture medium (GIBCO, Invitragen, USA); The RPMI1640 cell culture fluid (GIBCO, Invitragen, USA); Hyclone (GIBCO, Invitragen, USA); Superfine hyclone Fetal Bovine Serum (Hyclone).
Instrument: ultra cold storage freezer (Nature, USA), inverted microscope (NIKON, Japan), ELIASA (Bio-Tek Instruments, USA); Cell culture incubator (SANYO, Japan), superclean bench (FLC-Harbin Dong Lian instrument plant), the PH meter (Thermo orion, USA).
Experimental technique:
Adopt mtt assay by routine: with the ovarian cancer cell strain by conventional method cultivations of going down to posterity, the cell of collection exponential phase, the adjusting concentration of cell suspension is 5*10
4About individual/ml.
Cell suspension is added in 96 well culture plates, and each hole adds 180 μ l; Place 37 ℃ of constant incubators to cultivate 24h.
Gemcitabine, ceramide liposome 1 (ceramide liposome that embodiment 4 makes) and ceramide liposome 2 (ceramide liposome that embodiment 5 makes) are made into the solution of gradient concentration (0.75 μ g/ml, 1.5 μ g/ml, 3 μ g/ml) respectively with the DMEM cell culture fluid.Experimental group adds Jixitabin solution (A), ceramide liposome 1+ gemcitabine mixed solution (B), the ceramide liposome 2+ gemcitabine mixed solution (C) of each concentration; They add by above-mentioned concentration simultaneously; Every hole adds 20 μ l; Establish 4 parallel holes for every group, and establish blank well (only adding the DMEM cell culture fluid) with zeroing.
Cultivate 48h at 37 ℃ of incubators, with the exhaustion of the liquid in 96 well culture plates, it is the MTT solution of 1mg/ml that every then hole adds 30 μ l concentration, puts 37 ℃, 5%CO with liquid-transfering gun
2Incubator continue to cultivate 4h.Abandon supernatant, every hole adds dimethyl sulfoxine (DMSO) 150 μ l, puts shaking table and shakes up 30min, under 492nm, detects every hole absorbance (A) value with ELIASA, uses SPSS software statistics experimental result then, and is specifically as shown in Figure 7.
Can find out that by Fig. 7 the cell survival rate that the CaOV3 human oophoroma cell line singly adds ectogenic Jixitabin solution different time has significant difference (cell survival detects with general MTT method).Associating or combination give the survival rate that gemcitabine and ceramide liposome have significantly reduced the CaOV3 Proliferation of Human Ovarian Cell, cause the CaOV3 human oophoroma cell line significantly dead, obviously are superior to the ovarian cancer resistance effect of list with gemcitabine.
Embodiment 13: ceramide liposome and ceramide antitumaous effect are relatively.
The test cell: the L3.6 pancreas cancer cell strain derives from US mode culture collection warehousing (ATCC).
Test drug and reagent: ceramide (Avanti, USA), 3-(4,5-dimethylthiazole-2)-2,5-diphenyl tetrazole bromine salt (MTT) (sigma, USA); Trypsin sigma, USA); Dimethyl sulfoxine (DMSO) (sigma, USA); The DMEM cell culture medium (GIBCO, Invitragen, USA); The RPMI1640 cell culture fluid (GIBCO, Invitragen, USA); Hyclone (GIBCO, Invitragen, USA); Superfine hyclone Fetal Bovine Serum (Hyclone).
Instrument: ultra cold storage freezer (Nature, USA), inverted microscope (NIKON, Japan), ELIASA (Bio-Tek Instruments, USA); Cell culture incubator (SANYO, Japan), superclean bench (FLC-Harbin Dong Lian instrument plant), the PH meter (Thermo orion, USA).
Experimental technique:
Adopt mtt assay by routine: with the L3.6 pancreas cancer cell strain by conventional method cultivations of going down to posterity, the cell of collection exponential phase, the adjusting concentration of cell suspension is 5*10
4About individual/ml.
Cell suspension is added in 96 well culture plates, and each hole adds 180 μ l; Place 37 ℃ of constant incubators to cultivate 24h.
Experimental group be divided into be 2 greatly the group, first group only adds ceramide or ceramide liposome, second largest group the utilization gemcitabine the basis on add ceramide or ceramide liposome.The corresponding respectively matched group of A, B, C, D, E, add ceramide liposome 1, add ceramide liposome 2, add the C6 ceramide (1 μ g/ml), add C6 ceramide (10 μ g/ml).Be specially: the A group does not add ceramide; The B group adds the ceramide liposome 1 (ceramide liposome that embodiment 4 makes) of 1 μ g/ml; The C group adds the ceramide liposome 2 (ceramide liposome that embodiment 5 makes) of 1 μ g/ml; The D group adds the C6 ceramide of 1 μ g/ml of free state, and the E group adds the C6 ceramide of 10 μ g/ml of free state; Every hole adds 20 μ l, establishes 4 parallel holes for every group, and these five experimental grouies are established matched group (only adding the DMEM cell culture fluid) simultaneously, with zeroing.
Cultivate 48h at 37 ℃ of incubators, with the exhaustion of the liquid in 96 well culture plates, it is the MTT solution of 1mg/ml that every then hole adds 30 μ l concentration, puts 37 ℃, 5%CO with liquid-transfering gun
2Incubator continue to cultivate 4h.Abandon supernatant, every hole adds dimethyl sulfoxine (DMSO) 150 μ l, puts shaking table and shakes up 30min, under 492nm, detects every hole absorbance (A) value with ELIASA, uses SPSS software statistics experimental result then, and is specifically as shown in Figure 8.
Can find out by Fig. 8: can promote pancreatic cancer cell dead behind the ceramide of liposome and the gemcitabine drug combination more efficiently.The ceramide of liposome only needs 1 μ g/ml just can reach the effect of free ceramide 10 μ g/ml, and the free state ceramide of low concentration does not almost have influence (Fig. 8) to the cancer cell death of induced by chemotherapeutic agents on an equal basis.Prompting lipid physical ability effectively promotes ceramide to get in the cell, and low concentration (Cf 10%) liposome ceramide can significantly increase the chemosensitivity of gemcitabine to cancer of pancreas.
Claims (10)
1. ceramide liposome comprises a treatment effective amount of actives and a type lipid bilayer thin film, and it is characterized in that: the weight portion of said active component is 0.5-20 part, and active component is a ceramide; The weight portion of said type of lipid bilayer thin film is 10-350 part, comprises following components by part by weight: phospholipid substance 5-100 part, cholesterol 0.5-10 part, surfactant 0-100 part, additives 0-20 part, organic solvent 0.5-10 part.
2. ceramide liposome as claimed in claim 1 is characterized in that: described phospholipid substance is selected from one or more in two Laurel phosphatidyl cholines, DSPC, distearyl phosphatidyl glycerol, Phosphatidylserine, phosphatidylinositols, two palmityl phosphatidic acid, dioleoyl phospholipid phatidylcholine, dimyristoyl phosphatidyl choline, phosphatidyl glycerol, phosphatidic acid, phosphatidylcholine, dipalmitoyl phosphatidyl choline, two palmityl phosphatidyls, DOPE, soybean lecithin, Ovum Gallus domesticus Flavus lecithin, cephalin, synthetic phospholipid, the hydrogenated soy phosphatidyl choline; It is the natural cholesterol of raw material production that said cholesterol is selected for use with egg yolk, animal brains, lanoline; Said surfactant is selected from one or more the compositions in dexycholate, cholate, deoxycholic acid, cholic acid, tween 80, taurocholate, the poloxamer; Said organic solvent is selected from one or more the mixture in ethanol, acetone, methanol, chloroform, ether, the isopropyl alcohol; Said additives are selected from one or more among L-isoleucine, malic acid, sodium metabisulfite, sodium sulfite, vitamin C, vitamin E, propyl gallate, fumaric acid, L-cysteine or PH buffer agent phosphate, the EDTA.
3. ceramide liposome as claimed in claim 1; It is characterized in that: said ceramide liposome adds long circulation adjuvant; Carry out finishing and process long circulating liposomes, the mol ratio of long circulation adjuvant of said long circulation adjuvant and phospholipid substance is 1:10-1:200; Said long circulation adjuvant is selected from Polyethylene Glycol-phospholipid derivative, Polyethylene Glycol, polyvinylpyrrolidone, methyl and gathers azoles quinoline, Polyethylene Glycol-dipalmitoyl phosphatidyl choline, Polyethylene Glycol-distearyl acyl group PHOSPHATIDYL ETHANOLAMINE, chitosan or polyvinyl alcohol.
4. ceramide liposome as claimed in claim 1 is characterized in that: said ceramide liposome adds the magnetic decorative material, carries out finishing and processes magnetic liposome; Said magnetic decorative material is a super-fine magnetic powder.
5. ceramide liposome as claimed in claim 1 is characterized in that: said ceramide liposome adds the temperature-sensitive auxiliary material, carries out finishing and processes thermal sensitive liposome; Said temperature-sensitive auxiliary material are the phospholipid that itself has thermal sensitivity, comprise dipalmitoyl phosphatidyl choline (DPPC), DSPC (DSPC); Or the macromolecule thermally sensitive polymeric, comprise polyacrylic acid, gather phosphatidic acid; Or a kind of phase transition temperature that can make liposome is suitable for the oiliness medicine of tumor thermotherapy temperature, comprises elemene or wild duck seed oil.
6. ceramide liposome as claimed in claim 1 is characterized in that: the mean diameter of said ceramide liposome decentralized photo is less than 500nm; Said ceramide liposome exists with the form of injection or solid powder; Said ceramide liposome envelop rate is greater than 80%.
7. the method for preparing of ceramide liposome; It is characterized in that; Comprise the steps: fully to be dissolved in ceramide, phospholipid substance, cholesterol and additives in the organic solvent; In disperse medium, adopt film dispersion method or organic solvent injection method to make ceramide liposome surfactant dissolves, adopt ultrasonic, high pressure homogenize then or the method extruded is reduced to below the 500nm mean diameter of the ceramide liposome that makes and uniform distribution.
8. the method for preparing of ceramide liposome as claimed in claim 7, it is characterized in that: said disperse medium is Tris buffer, water, phosphate buffer, carbonate buffer solution, 5% D/W or 0.9%NaCl solution; The weight concentration of the surfactant in the said disperse medium is 1%-30%.
9. the method for preparing of ceramide liposome as claimed in claim 7 is characterized in that: in the ceramide liposome that makes, add the lyophilized powder protective agent, process lyophilized powder through spray drying or freeze drying process; Said lyophilized powder protective agent is selected from one or more in mannitol, sucrose, trehalose, sodium chloride, glucose, dextran, glycine, lactose, sorbitol, xylitol, fructose, glycerol, arabic gum and the lysine; The lyophilized powder protective agent: the parts by weight proportioning of ceramide liposome is 10-20:0.5-6.0.
10. each described ceramide liposome of claim 1 ~ 6 is in the purposes of preparation in the antitumor drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100664643A CN102805730A (en) | 2012-03-14 | 2012-03-14 | Ceramide liposome and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100664643A CN102805730A (en) | 2012-03-14 | 2012-03-14 | Ceramide liposome and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102805730A true CN102805730A (en) | 2012-12-05 |
Family
ID=47229716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100664643A Pending CN102805730A (en) | 2012-03-14 | 2012-03-14 | Ceramide liposome and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102805730A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140234403A1 (en) * | 2011-09-20 | 2014-08-21 | Glaxosmithkline Biologicals Sa | Liposome production using isopropanol |
| CN104306334A (en) * | 2014-10-20 | 2015-01-28 | 河南牧翔动物药业有限公司 | Aivlosin tartrate lipidosome as well as suspension and lipidosome powder |
| WO2015136479A1 (en) * | 2014-03-12 | 2015-09-17 | Glaxosmithkline Biologicals S.A. | Liposomal compositions for mucosal delivery |
| CN105078779A (en) * | 2015-09-09 | 2015-11-25 | 珠海市雅莎生物科技有限公司 | Preparation method of water-based ceramide |
| CN105651987A (en) * | 2016-01-29 | 2016-06-08 | 苏州联辰生物技术有限公司 | Method for manufacturing novel nano beam concentration material |
| CN106581695A (en) * | 2016-10-27 | 2017-04-26 | 山东省分析测试中心 | Cationic liposome, preparation method and applications thereof |
| CN107028810A (en) * | 2017-04-06 | 2017-08-11 | 湖南御家化妆品制造有限公司 | A kind of transdermal moisturizing combination and the application in cosmetics are prepared |
| CN109453043A (en) * | 2018-12-13 | 2019-03-12 | 诺斯贝尔化妆品股份有限公司 | Nano emulsion with good stability |
| TWI760901B (en) * | 2020-10-23 | 2022-04-11 | 大江生醫股份有限公司 | Manufacturing method for a liposome with ability to stably encapsulating active ingredient |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101102752A (en) * | 2004-11-15 | 2008-01-09 | 耶路撒冷希伯来大学伊萨姆研发公司 | Combination therapy associating preferably a ceramide with acytotoxic drug |
| CN101129361A (en) * | 2007-07-17 | 2008-02-27 | 山东华诺生物科技有限公司 | Sirolimus lipidosome freeze-dried acanthopanax powder and technique of preparing the same |
-
2012
- 2012-03-14 CN CN2012100664643A patent/CN102805730A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101102752A (en) * | 2004-11-15 | 2008-01-09 | 耶路撒冷希伯来大学伊萨姆研发公司 | Combination therapy associating preferably a ceramide with acytotoxic drug |
| CN101129361A (en) * | 2007-07-17 | 2008-02-27 | 山东华诺生物科技有限公司 | Sirolimus lipidosome freeze-dried acanthopanax powder and technique of preparing the same |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140234403A1 (en) * | 2011-09-20 | 2014-08-21 | Glaxosmithkline Biologicals Sa | Liposome production using isopropanol |
| BE1022346B1 (en) * | 2014-03-12 | 2016-03-25 | Glaxosmithkline Biologicals S.A. | LIPOSOMAL COMPOSITIONS FOR MUCOSAL ADMINISTRATION |
| WO2015136479A1 (en) * | 2014-03-12 | 2015-09-17 | Glaxosmithkline Biologicals S.A. | Liposomal compositions for mucosal delivery |
| CN106456546A (en) * | 2014-03-12 | 2017-02-22 | 葛兰素史密丝克莱恩生物有限公司 | Liposomal compositions for mucosal delivery |
| CN104306334B (en) * | 2014-10-20 | 2017-08-29 | 河南牧翔动物药业有限公司 | Safe ten thousand rhzomorph liposomes and its suspension and liposome powder |
| CN104306334A (en) * | 2014-10-20 | 2015-01-28 | 河南牧翔动物药业有限公司 | Aivlosin tartrate lipidosome as well as suspension and lipidosome powder |
| CN105078779A (en) * | 2015-09-09 | 2015-11-25 | 珠海市雅莎生物科技有限公司 | Preparation method of water-based ceramide |
| CN105651987A (en) * | 2016-01-29 | 2016-06-08 | 苏州联辰生物技术有限公司 | Method for manufacturing novel nano beam concentration material |
| CN106581695A (en) * | 2016-10-27 | 2017-04-26 | 山东省分析测试中心 | Cationic liposome, preparation method and applications thereof |
| CN107028810A (en) * | 2017-04-06 | 2017-08-11 | 湖南御家化妆品制造有限公司 | A kind of transdermal moisturizing combination and the application in cosmetics are prepared |
| CN107028810B (en) * | 2017-04-06 | 2018-03-27 | 湖南御家化妆品制造有限公司 | A kind of transdermal moisturizing combination and the application in cosmetics are prepared |
| CN109453043A (en) * | 2018-12-13 | 2019-03-12 | 诺斯贝尔化妆品股份有限公司 | Nano emulsion with good stability |
| CN109453043B (en) * | 2018-12-13 | 2021-09-28 | 诺斯贝尔化妆品股份有限公司 | Nano emulsion with good stability |
| TWI760901B (en) * | 2020-10-23 | 2022-04-11 | 大江生醫股份有限公司 | Manufacturing method for a liposome with ability to stably encapsulating active ingredient |
| US11497728B2 (en) | 2020-10-23 | 2022-11-15 | Tci Co., Ltd. | Preparation method for liposome having ability to stably encapsulate active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102805730A (en) | Ceramide liposome and preparation method and application thereof | |
| TWI362931B (en) | Irinotecan formulation | |
| JP2006513984A (en) | Pharmaceutically active, lipid-based SN38 formulation | |
| WO2011066684A1 (en) | Liposome of irinotecan or its hydrochloride and preparation method thereof | |
| CN103479578B (en) | The Liposomal formulation of a kind of maleic acid Pixantrone and preparation technology thereof | |
| BRPI0720733A2 (en) | LIPOSOMIC PHARMACEUTICAL PREPARATION AND METHOD FOR MANUFACTURING THE SAME. | |
| CN101579312B (en) | Teniposide liposome and preparation method thereof | |
| BRPI0619565A2 (en) | liposome compositions | |
| CN105777770B (en) | A kind of the 7-Ethyl-10-hydroxycamptothecin compound and its long circulating liposome of saturated long chain fatty acid modification | |
| JP2008534525A (en) | Nanomicelle formulation of anthracycline antitumor antibiotic encapsulated in polyethylene glycol derivative of phospholipid | |
| CN111920768A (en) | A molecular targeting drug liposome and its application in the preparation of tumor drugs | |
| CN107753429A (en) | A kind of preparation of Norcantharidin Liver targeting liposome and its application of lyophilized formulations | |
| CN116033906A (en) | Liposome formulation | |
| JPWO2017188350A1 (en) | How to inhibit tumor growth | |
| CN108567742A (en) | SN38 lipid compositions, preparation method and use | |
| CN102755292A (en) | Vesicle-type medication system containing metformin, and application thereof | |
| CN101455641B (en) | Anti-cancer medicine liposome preparation sensitive to ray | |
| CN101322681B (en) | A kind of method for preparing the nano micellar preparation of anthracycline antitumor antibiotic | |
| US8298573B2 (en) | Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs | |
| CN105796495B (en) | Irinotecan hydrochloride liposome pharmaceutical composition and preparation method thereof | |
| CN102274185A (en) | Antitumor pH-sensitive liposome and freeze-dried powder injection thereof, and preparation methods thereof | |
| CN1980671B (en) | Liposome preparation containing slightly water-soluble camptothecin | |
| Vijeta et al. | Transethosomes: A Novel carrier for transcutaneous drug delivery an overview | |
| CN101411690A (en) | 2-methoxyestradiol lipidosome freeze-dried injection and preparation method thereof | |
| CN103690556B (en) | A kind of hydroxy camptothecin long cyclic liposome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121205 |